Treatment of septic shock

Details Treatment of septic shock Treatment of septic shock

1997-08-27

2002-10-15

Travers, Russell (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heavy metal containing doai

C514S574000, C424S647000, C424S648000

Reexamination Certificate

active

06465511

ABSTRACT:

The present invention relates to the use of transition metal complexes for the treatment of septic shock, and in particular the hypotension associated therewith.
Garavilla et al. (Drug. Dev. Res. 25:139-148, (1992)) disclose deferoxamine-manganese complexes which are superoxide dismutase mimics and improve survival following haemorrhagic and endotoxic shock. Sanan et al. (Pharmacos 28:103-105, (1985)) disclose the use of desferrioxamine mesylate to increase the survival rate of anaesthetised dogs subjected to haemorrhagic shock. U.S. Pat. No. 5,296,466 discloses the use of an iron hemoprotien for the treatment of systemic hypotension or other pathogenic syndromes induced by inappropriate NO production.
It has now been found that transition metal complexes increase the survival rate in mice subjected to endotoxin induced septic shock. The term ‘transition metal complex’ will be understood by one skilled in the art as a transition metal which is linked to one or more chelating agents (ligands). All transition metal complexes other than deferoxamine-maganese, hemin, diehtyldithiocarbamic acid complexes and iron hemoproteins are included.
Accordingly the present invention provides the use of a transition metal complex as hereinbefore defined in the manufacture of a medicament for the treatment of septic shock and in particular the hypotension associated therewith. Alternatively, there is provided a method of treating septic shock and in particular the hypotension associated therewith comprising administering to a mammal in need thereof an effective amount of a transition metal complex as hereinbefore defined.
Suitable transition metals include iron, copper, silver, zinc, manganese and nickel. Iron is a particularly preferred transition metal.
Suitable chelating agents include those that are coordinated to the transition metal through one or more nitrogen atoms which may be contained in a polycyclic ring system or as a substituent in an alkylene chain: through an O
−
or S
−
anion; or by virtue of a pair of electrons.
Preferred ligands include:
(i) those of formula (I)
 wherein Q and Q′ may be the same or different and are independently a C
2-10
alkylene chain. Most preferably Q is a C
5
-alkylene chain and Q′ is a C
2
-alkylene chain.
(ii) those of formula (II)
(iii) those of formula (III)
(iv) those of formula (IV)
 wherein R
16
is C
1-6
alkyl chain optionally substituted by a group CO
2
H or a group NR
17
R
18
wherein R
17
and R
18
are independently selected from hydrogen or C
1-4
alkyl optionally substituted by a group CO
2
H.
(v) those of formula (V)
(vi) those of formula (VI)
(vii) those of formula (VII)
(viii) those-of formula (VIII)
 wherein n is 1 to 6, preferably 2.
(ix) those of formula (IX)
 wherein R is a C
1-6
sulphonic acid or carboxylic acid group.
(x) those of formula (X)
(xi) those of formula
NH
3
The ligands hereinbefore described are shown in their neutral form, although they can also exist in ionic form, e.g. as a cation or anion. The exact stoichiometry of metal to ligand depends on their electronic properties, e.g. charge and the number of coordination centres. The invention is intended to include all possible stoichriometric alternatives.
Specifically preferred complexes include:
Ferrioxamine B
Ferric Pyridoxal Isonicotinoyl Hydrazone
Tris (acetylacetonato)manganese (III)
iron (III) citrate
Diethylenetriaminepentaacetic acid Iron (III)
Ethylenediaminetetraacetic acid Iron (III)
Ferrous gluconate
1,1′-ferrocenedimethanol
Ethyl &agr;-acetyl-4-(methoxycarbonyl)benzoylacetate, Copper (II)
Tris (ethylenediamine) nickel (II) sulfate
Hexaaminenickel (II) Chloride
Bathopheneanthroline disulphonic acid
Most preferred complexes are ferrioxamine B and diethylenetriaminepentaacetic acid Iron (III).
It is believed that the transition metal complexes of the present invention may act by scavenging nitric oxide (NO) in the body. Therefore, in addition to being of use in the treatment of septic shock the transition metal complexes may also be of use in the treatment of other conditions caused by pathological NO production. Accordingly the present invention further provides the use of a transition metal complex in the manufacture of a medicament for the treatment of conditions caused by pathological NO production.
A transition metal complex of the present invention may be of use during therapy with cytokines such as TNF, IL-1 and IL-2 or therapy with cytokine-inducing agents, for example 5,6-dimethyl xanthenone acetic acid; as an adjuvant to short term immunosuppression in transplant therapy; in patients suffering from inflammatory conditions in which an excess of NO contributes to the pathophysiology of the condition, for example adult respiratory distress syndrome and myocarditis; and in autoimmune and/or inflammatory conditions, such as arthritis and rheumatoid arthritis. Other conditions in which such transition metal complexes may be of use include cerebral ischemia, CNS trauma, epilepsy, AIDS dementia, chronic pain, schizophrenia and conditions in which non-adrenegic, non-cholinergic nerve may be implicated such as priapism, obesity and hyperphagia.
The transition metal complexes of the present invention may be administered alone or in conjunction with another therapeutic agent, for example a NO synthase inhibitor such as an arginine derivative e.g., L-NMMA. Accordingly, a yet further aspect of the invention provides the use of a transition metal complex in conjunction with a NO synthase inhibitor in the manufacture of a medicament for the treatment of conditions caused by pathological NO production.
A further aspect of the present invention provides a transition metal complex as hereinbefore defined other than ferrioxamine B for use in medicine.
Whilst it may be possible for the transition metal complexes to be administered as the raw chemical, it is preferable to present them as a pharmaceutical formulation. According to a further aspect, the present invention provides a pharmaceutical formulation comprising a transition metal complex as hereinbefore defined other than ferrioxamine B together with one or more pharmaceutically acceptable carriers therefor and optionally one or more other therapeutic ingredients. The carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
The formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous and intraarticular), rectal and topical (including dermal, buccal, sublingual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient. Most suitably, the formulation is suitable for oral or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the transition metal complex (“active ingredient”) with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.
A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free

Affiliated with

Also associated with

Rating

Treatment of septic shock does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of septic shock, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of septic shock will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2973570